Anti-obesity drugs: status quo and recent advances.
10.3881/j.issn.1000-503X.2011.03.007
- Author:
Hui-juan ZHU
1
;
Zi-meng JIN
Author Information
1. Key Laboratory of Endocrinology of Ministry of Health, Department of Endocrinology,ʤPUMC Hospital, CAMS and PUMC, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
Anti-Obesity Agents;
therapeutic use;
Appetite Depressants;
therapeutic use;
Glucagon-Like Peptide 1;
therapeutic use;
Humans;
Obesity;
drug therapy
- From:
Acta Academiae Medicinae Sinicae
2011;33(3):243-247
- CountryChina
- Language:English
-
Abstract:
Obesity has become a major health problem worldwide. The prevalence and morbidity of obesity-related diseases including diabetes, hypertension, cerebro-cardiovascular diseases, and tumors also have remarkably increased. Treatment of obesity poses a challenge for clinicians. Anti-obesity treatment is helpful to improve and even reverse obesity-related complications. Diet control and physical exercises remain the predominant interventions for obese patients. Anti-obesity drugs can be considered in those who respond poorly to behavioral intervention or those who have developed obesity-related complications. The commonly used anti-obesity drugs include gastrointestinal lipase inhibitors and appetite suppressants. Glucagon-like peptide 1 has also been found to be effective in reducing body weight. Some more drugs are under development, which include selective 5-HT 2c agonist, β3 receptor agonist, and melanocortin receptor 4 agonist, may also be promising.
